List of Excipients in Branded Drug PROHANCE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bracco Diagnostics Inc	PROHANCE	gadoteridol	0270-1111	CALTERIDOL CALCIUM
Bracco Diagnostics Inc	PROHANCE	gadoteridol	0270-1111	TROMETHAMINE

ProHance Excipient Strategy and Commercial Opportunities in Gadoteridol MRI Contrast

Last updated: October 1, 2026

ProHance is a gadolinium-based contrast agent containing gadoteridol, a macrocyclic, nonionic gadolinium chelate. Its commercial formulation is deliberately simple: gadoteridol in water for injection, with tromethamine as a stabilizing or buffering excipient and hydrochloric acid used for pH adjustment. The strongest commercial opportunities are unlikely to come from novel excipient chemistry alone. They are more likely to arise from manufacturing efficiency, container systems, dose optimization, supply reliability, and differentiated presentations for hospitals and imaging centers.

What excipients are used in ProHance?

ProHance contains a limited excipient package designed to support chemical stability, pH control, sterility, and injectable performance.

Component	Function	Approximate label status
Gadoteridol	Active gadolinium chelate	279.3 mg/mL, equivalent to 0.5 mmol/mL
Tromethamine	Buffering and formulation stabilizer	Approximately 1.21 mg/mL
Hydrochloric acid	pH adjustment	Quantity sufficient
Water for injection	Vehicle	Quantity sufficient

The commercial injection is preservative-free. The labeled pH is approximately 6.5 to 8.0, and osmolality is approximately 630 mOsm/kg water at the 0.5 mmol/mL concentration.[1]

The low-excipient design reduces compatibility risks and simplifies regulatory characterization. It also limits opportunities to claim a broad formulation patent based solely on excipient selection.

Why does ProHance use tromethamine?

Tromethamine, also known as TRIS, provides buffering capacity in an injectable aqueous formulation. For gadolinium chelates, pH control is commercially important because the product must maintain the integrity of the chelate during storage and administration.

The excipient can affect:

• Long-term chemical stability
• Resistance to pH drift
• Compatibility with glass vials, elastomeric closures, and syringes
• Particulate formation
• Extractables and leachables profiles
• Manufacture and filling performance

The formulation does not rely on a complex surfactant, polymer, lipid, or co-solvent system. That is strategically useful because it lowers formulation complexity, but it also makes it harder for a competitor to obtain meaningful differentiation through conventional excipient substitution.

How strong is the ProHance formulation strategy?

The formulation strategy is technically conservative and commercially practical. It uses a single aqueous phase, a low excipient burden, and a nonionic macrocyclic chelate.

Strengths

The main strengths are:

1. Reduced excipient-related safety exposure.
2. Simple sterile manufacturing.
3. Compatibility with conventional vial and syringe packaging.
4. Straightforward quality control.
5. Lower risk of precipitation or phase separation.
6. Familiar handling in hospital radiology departments.

The macrocyclic structure of gadoteridol is part of the active pharmaceutical ingredient rather than an excipient advantage. It provides a relatively stable gadolinium complex compared with less kinetically stable linear agents, although the clinical safety profile depends on the product, patient population, renal function, dosing, and regulatory labeling.[1,2]

Limitations

A simple formulation creates several commercial constraints:

• It provides limited room for lifecycle innovation.
• Most excipient substitutions would be difficult to distinguish clinically.
• A new buffer system would require stability and compatibility evidence.
• A lower-osmolality version may require a different concentration or active composition.
• Excipient changes may affect chelate stability and impurity profiles.
• The product’s principal value remains the gadoteridol molecule and its delivery format.

For a generic manufacturer, the simplest route is generally to reproduce the reference product’s qualitative and quantitative formulation as closely as permitted, rather than introduce an unnecessary excipient difference.

What formulation patents protect ProHance?

Publicly available product information identifies ProHance as a gadoteridol injection marketed by Bracco Diagnostics. The product’s principal historical protection is associated with the gadoteridol active ingredient and its use as a diagnostic imaging agent, rather than with a commercially complex excipient platform.

A formulation-focused review should separate four categories of intellectual property:

IP category	Relevance to ProHance	Commercial implication
Gadoteridol composition-of-matter patents	Historically central	Likely no longer the main barrier to conventional generic development
Chelate synthesis and purification patents	May affect manufacturing route	Can create process risk even after composition patents expire
Aqueous formulation patents	Potentially relevant to pH, stability, concentration, or packaging	Strength depends on claim scope and expiration
Method-of-use patents	May cover imaging populations or diagnostic applications	Risk depends on labeling and proposed generic indications

The key issue is not whether a patent once covered gadoteridol. The key issue is whether any unexpired, enforceable patent claims cover the proposed formulation, manufacturing process, delivery device, or labeled use.

Are excipient patents likely to block a ProHance generic?

A broad blocking patent based only on tromethamine, water for injection, and pH adjustment would generally be difficult to sustain if similar aqueous gadolinium formulations were known before the relevant filing date. More defensible claims could involve:

• Narrow pH ranges linked to improved stability
• Defined impurity limits after accelerated storage
• Specific container-closure systems
• Low-particulate formulations
• Manufacturing conditions that reduce free gadolinium
• Pre-filled syringe materials with improved compatibility
• Specific concentration or dosing configurations

These claims would need to provide more than routine formulation optimization. The commercial value of any such patent depends on claim breadth, prosecution history, validity, and whether the claims read on a substitutable generic product.

When does ProHance lose exclusivity?

ProHance is a small-molecule diagnostic drug, not a biologic. A competing product would generally pursue an abbreviated new drug application, or ANDA, rather than a biosimilar application.

The practical exclusivity analysis includes:

Exclusivity issue	Relevance
New chemical entity exclusivity	Historical issue, not the current principal barrier
Patent exclusivity	Depends on unexpired claims covering gadoteridol, formulation, use, or manufacturing
Pediatric exclusivity	Must be assessed from FDA records and applicable extensions
Orphan exclusivity	Generally not the principal commercial framework for ProHance
Regulatory exclusivity for a new formulation	Could apply if a genuinely new product receives separate approval
Trade-secret protection	May affect manufacturing know-how but does not block an independent process

A precise generic-entry date cannot be established from the product label alone. The relevant date is the earliest point at which all blocking patents and regulatory exclusivities cease to prevent approval or commercial launch.

What is the FDA regulatory status of ProHance?

ProHance is an FDA-approved gadolinium-based contrast agent for magnetic resonance imaging. The FDA labeling covers diagnostic MRI applications, including central nervous system imaging, with pediatric use reflected in the current labeling.[1]

The product is administered intravenously and is supplied in multiple single-dose presentations. Its regulatory profile is based on:

• Gadoteridol identity and strength
• Sterility
• Endotoxin limits
• Particulate control
• Chelate stability
• Assay and impurity controls
• Container-closure integrity
• Compatibility with the labeled administration route

An ANDA sponsor would need to establish pharmaceutical equivalence and bioequivalence or meet the applicable alternative requirements for an injectable diagnostic product. For an injectable solution, the formulation, strength, route, dosage form, active ingredient, and quality attributes are central.

What commercial opportunities exist in ProHance excipients?

The largest opportunity is not likely to be a premium “excipient-enhanced” version. The better opportunities involve cost, reliability, packaging, and operational performance.

1. Dual-source tromethamine and raw materials

Tromethamine is a commodity pharmaceutical excipient, but supply disruptions can affect sterile drug manufacturing. Suppliers can differentiate through:

• Compendial quality
• Low bioburden material
• Consistent particle profile
• Global regulatory files
• Reliable batch release
• Regional supply redundancy

For the finished product manufacturer, dual sourcing can reduce dependence on one excipient supplier. The value is highest when the supplier can support change-control documentation and regulatory submissions.

2. Ready-to-use prefilled syringes

Prefilled syringes can reduce preparation steps, dosing errors, and vial waste in high-throughput imaging centers. The commercial barrier is container compatibility, not the excipient itself.

Development priorities include:

• Low tungsten and low extractables glass
• Elastomer compatibility
• Silicone control
• Reduced adsorption
• Container-closure integrity
• Mechanical performance during injector use
• Stability across refrigerated and controlled-room-temperature conditions

A prefilled syringe may qualify as a lifecycle product if it improves workflow without changing the active concentration or clinical use. Its commercial success depends on procurement economics and compatibility with automated MRI injectors.

3. Lower-waste vial sizes

Imaging departments often face dose wastage because product presentations do not match patient weight, scanning protocol, or scheduling volume. A portfolio that includes smaller and larger single-dose containers can reduce discard volume.

Potential presentations include:

• Small-volume pediatric or low-weight doses
• Standard adult single-dose vials
• High-throughput multi-patient workflow formats where permitted
• Pre-filled syringes aligned with injector settings

ProHance’s preservative-free status limits the use of multi-dose containers unless the manufacturer can satisfy the applicable sterility and preservative requirements. Single-dose optimization is therefore the more realistic path.

4. Manufacturing process differentiation

Process patents and know-how may create more defensible value than a new excipient. Areas of interest include:

• Higher-yield gadoteridol synthesis
• Removal of residual free gadolinium
• Control of regioisomeric or process-related impurities
• Reduced metal contamination
• Improved filtration and filling yields
• Reduced particulate formation
• More efficient sterile filtration

These improvements can lower cost of goods without changing the approved excipient profile. They may also support a manufacturing patent if the process produces a measurable product attribute that is difficult to replicate.

5. Stability-enhancing formulation work

A competing formulation could evaluate alternative buffers, including phosphate or other pharmaceutically acceptable systems. The commercial case is weak unless the change provides a demonstrated benefit, such as:

• Longer shelf life
• Lower storage temperature
• Reduced impurity growth
• Better compatibility with a syringe system
• Improved resistance to shipping excursions

Changing the buffer is not automatically advantageous. A new excipient can introduce new impurity pathways, require additional toxicology justification, and complicate regulatory comparability.

Which companies are challenging ProHance?

The competitive landscape includes branded gadolinium agents and potential generic manufacturers. Direct competition comes from other macrocyclic agents, including Gadavist, marketed by Bayer, and Dotarem, marketed by Guerbet, as well as linear agents and other gadolinium products.

Product	Active ingredient	Structural class	Commercial relevance
ProHance	Gadoteridol	Macrocyclic, nonionic	Reference product for gadoteridol
Gadavist	Gadobutrol	Macrocyclic, nonionic	Competes on macrocyclic profile and concentration
Dotarem	Gadoterate meglumine	Macrocyclic, ionic	Competes in broad MRI contrast use
MultiHance	Gadobenate dimeglumine	Linear, ionic	Competes in selected imaging applications
Magnevist and other legacy products	Gado­pentetate dimeglumine and others	Linear	Reduced strategic importance in some markets

The principal competitive factors are:

• Gadolinium retention and safety positioning
• Macrocyclic versus linear structure
• Product concentration
• Price per dose
• Pediatric labeling
• Hospital formulary status
• Supply reliability
• Injector compatibility
• Contracting and group purchasing arrangements

Is biosimilar risk relevant to ProHance?

No. ProHance is a synthetic small-molecule gadolinium chelate, not a biologic. The relevant competitive risk is generic or follow-on injectable competition, not biosimilar substitution.

A generic entrant would likely compete through:

• Lower acquisition cost
• Equivalent concentration and dosage form
• Hospital contracting
• Reliable supply
• Compatible packaging
• Multiple vial sizes
• Efficient distribution

The principal technical risk for a generic manufacturer is demonstrating equivalence and controlling metal-related impurities, not proving biosimilarity.

What generic launch scenarios exist for ProHance?

Three launch scenarios are commercially plausible.

Standard injectable generic

A manufacturer reproduces the reference aqueous formulation, concentration, dosage form, and route. This is the most direct strategy and likely the lowest regulatory risk.

Differentiated container presentation

A manufacturer offers a prefilled syringe, injector-compatible format, or improved vial portfolio. The formulation may remain substantially unchanged, while the commercial differentiation comes from workflow and waste reduction.

Process-led low-cost entry

A manufacturer uses a lower-cost synthesis or purification process while maintaining the reference formulation. This strategy can support aggressive hospital pricing but requires robust impurity control and supply reliability.

The most likely market impact would be gradual price erosion rather than immediate substitution across all imaging sites. Hospitals may retain multiple suppliers to protect supply continuity and preserve contracting leverage.

How does ProHance compare with competing gadolinium agents?

ProHance has a relatively clean formulation profile, but excipients are not the main differentiator against competing agents.

Factor	ProHance	Gadavist	Dotarem
Active chelate	Gadoteridol	Gadobutrol	Gadoterate meglumine
Macrocyclic	Yes	Yes	Yes
Ionic character	Nonionic	Nonionic	Ionic
Typical concentration	0.5 mmol/mL	1.0 mmol/mL	0.5 mmol/mL
Excipient strategy	Minimal aqueous system	Minimal aqueous system	Minimal aqueous system
Main commercial differentiator	Established gadoteridol platform	High concentration and dose volume	Macrocyclic ionic chelate and market presence

ProHance’s lower molar concentration than Gadavist can increase injection volume for an equivalent mmol dose. A competing product can use concentration and workflow as commercial differentiators, while ProHance can compete through established use, supply, contracting, and a simple formulation.

What is the commercial value of the ProHance patent estate?

The patent estate should be considered moderate for the finished formulation and potentially stronger for historical composition and manufacturing claims, subject to current claim status. The commercial value of any surviving rights depends on whether they cover:

• The marketed 0.5 mmol/mL product
• The tromethamine-buffered formulation
• The container system
• The manufacturing process
• The labeled pediatric or CNS use
• A commercially realistic generic design-around

A simple aqueous formulation generally offers less patent differentiation than a depot, liposomal, sustained-release, or device-integrated product. Manufacturing know-how and contracting strength may therefore have greater current commercial importance than excipient patent scope.

Key Takeaways

• ProHance contains gadoteridol, tromethamine, hydrochloric acid for pH adjustment, and water for injection.
• The formulation is preservative-free and technically simple.
• Tromethamine supports pH control and formulation stability but is unlikely, by itself, to create a strong blocking patent position.
• ProHance is subject to generic, not biosimilar, competitive risk.
• The strongest commercial opportunities are prefilled syringes, waste-reducing vial sizes, injector compatibility, supply redundancy, and lower-cost manufacturing.
• Process control over free gadolinium, metal impurities, particulates, and sterile filling may provide greater value than a new excipient system.
• Competing macrocyclic agents include Gadavist and Dotarem, with concentration, price, workflow, and contracting driving competition.
• A generic formulation that closely matches the reference product is likely to have the lowest regulatory and technical risk.

Frequently Asked Questions

Does ProHance contain a preservative?

No. ProHance is labeled as a preservative-free, single-dose injectable formulation.

Is tromethamine the active ingredient in ProHance?

No. Gadoteridol is the active ingredient. Tromethamine is an excipient used for buffering and formulation support.

Can a generic manufacturer use a different buffer from ProHance?

Potentially, but the alternative formulation would require appropriate stability, compatibility, quality, and regulatory support. Matching the reference formulation is generally the lower-risk strategy.

Does ProHance have a biosimilar pathway?

No. Gadoteridol is a synthetic small-molecule chelate. A competing product would generally use the generic injectable drug pathway rather than the biosimilar pathway.

What is the best commercial opportunity for a new ProHance competitor?

The strongest opportunity is a reliable, lower-cost generic supported by optimized vial sizes or a prefilled syringe that reduces imaging workflow time and product waste.

References

1. U.S. Food and Drug Administration. (2023). ProHance (gadoteridol) injection prescribing information. Bracco Diagnostics Inc.

2. U.S. Food and Drug Administration. (2022). Gadolinium-based contrast agents: Drug safety communication. FDA.

3. U.S. Food and Drug Administration. (2019). Abbreviated new drug application submissions: Pharmaceutical equivalence and bioequivalence considerations for injectable drug products. FDA.

4. U.S. Food and Drug Administration. (2020). FDA-approved drug products database. FDA.

5. American College of Radiology. (2024). ACR manual on contrast media. American College of Radiology.